[email protected] International Collaboration in FP7 Health Research Dr. Indridi...
29
[email protected] a.eu International Collaboration in FP7 Health Research Dr. Indridi Benediktsson Directorate Health Horizontal Aspects and Coordination
-
date post
18-Dec-2015 -
Category
Documents
-
view
219 -
download
0
Transcript of [email protected] International Collaboration in FP7 Health Research Dr. Indridi...
International Collaboration in FP7
Health Research
Dr. Indridi Benediktsson
Directorate Health
Horizontal Aspects and Coordination
Reminder:ALL RESEARCH TOPICS WERE OPEN FOR 3rd
COUNTRY PARTICIPANTS
• At least 3 organizations from EU and/or associated states
• In addition, “third country” participants were welcome
• Partners from the INCO target countries, could receive funding
Outcome of FP6
eerolii
comment sdsdasdasd
SIXTH FRAMEWORK PROGRAMME 2002-2006Participation by legal entities from third countries
European Union/Associated States (1)/Overseas Countries & Territories
Target countries of specific measures in support of international cooperation: eligible for participation and funding
(within limits of budget)
Other third countries: eligible for participation; funding if provision under RTD activity or essential for carrying out indirect action
Currently no cooperation
• € 2.4 billion for health research; 604 projects over the 4 years• Average success rate: 25.4% • Total number of participants: 7,426
Project type number av. EC contribution partners
Integrated Projects 119 € 10.0m 21
Networks of Excellence 40 € 9.3m 30
STRePs 322 € 2.2m 8
Coordination Actions 25 € 1.1m 19
Specific Support Actions 98 € 0.4m 6
Outcome of FP6
3rd countries’ participation in FP6 Health Research
In total: 245 participants from 51 third countries
Number of 3rd country participants in Health projects
Number of participants (Top Ten)
0
5
10
15
20
25
30
35
Timeframe for FP7 projects
20122006 2007 20142008 2009 2010 20152011 2013 2016
Official duration of FP7 2007-2013
Projects resulting from FP7 calls operating
Results from FP7 projects in use
Last projects startFirst projects startFirst calls Last projects end
2017 2018 2019 2020 2021
1. Health2. Food, agriculture, fisheries and biotechnology3. Information and communication technologies4. Nanosciences, nanotechnologies, materials
and new production technologies5. Energy6. Environment (including climate change)7. Transport (including aeronautics)8. Socio-economic sciences and the humanities9. Security and space
Euratom: Fusion energy research, nuclear fissionand radiation protection
Cooperation – Collaborative Research
Nine themes
+
FP1 FP2 FP3 FP4 FP5 FP6
Socio -economic
Transport
Environment
Industrial + materials tech.
ICT
Energy
Life Sciences*
FP7
Security + Space
Collaborative Research changing priorities (relative weight)
*from FP6 split into: Health + Food/Agri/Biotech
Objectives:
– Improving the health of European citizens
– Increasing the competitiveness of European health-related industries and business
– Addressing global health issues including emerging epidemics
Health Research
Rationale for pan-European approach (I):Sequencing of human genome
advances in post-genomics
vast amount of data, accelerated discovery
Translational research multidisciplinary
Health policy-driven research comparisons of national models & data
+
Health Research
Rationale for pan-European approach (II):
– Strong EU-based biomedical research strengthen the competitiveness of large industries (pharma) and SMEs (healthcare biotech & medical technology)
• Transnational co-operation is essential to face the worldwide competition
• Contribute to the development of norms & standards to set up appropriate legislative framework for new medical technologies (e.g. regenerative medicine)
Health Research
1. Health
Three pillars of activities:
• Biotechnology, generic tools and technologiesfor human health
• Translating research for human health
• Optimising the delivery of healthcare to European citizens
• Budget: €6 billion over 7 years (2007-2013)
1: Biotechnology, generic tools and technologies
High-throughput research (enhancing data generation, standardisation, acquisition & analysis)
Detection, diagnosis and monitoring (with emphasis on non-invasive or minimally invasive approaches)
Innovative therapeutic approaches and interventions(with potential application in many diseases and disorders)
Predicting suitability, safety and efficacy of therapies (biological markers, in vivo and in vitro methods and models, simulation, pharmacogenomics, targeting etc.)
Collaborative researchin Health
2: Translating research for human health
Integrating biological data and processes: (large-scale data gathering, systems biology)
Research on the brain and neurological diseases, human development and ageing
Infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics, NID)
Other major diseases: (cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)
Collaborative researchin Health
3: Optimising the delivery of health care
Enhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health etc.)
Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking etc.)
Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems etc.)
Collaborative researchin Health
The Innovative Medicines Initiative
Starting point:– drug development: increasing cost, duration and risk– competitiveness of pharmaceutical industry affected– EU concerned by loss of leadership in pharma R&D
Response: the Innovative Medicines Initiative– collaborative effort between EC and pharmaceutical
industry (EFPIA) – tackle specific issues where research is the key – Public Private Partnership for implementation
Calls for proposals in 2007
Health theme
•First calls for proposals issued 22 Dec.’06 first deadline: 19 April 2007 €628 million second deadline: 18 September 2007 €532 million1
[ not all areas will be open in each call ]
1: pending approval of 2008 budget
Evaluation
Peer review by invited experts
Criteria:• S+T quality
-of the concept, objectives and methodology
• Impact-potential impact, dissemination, exploitation, use
• Implementation-management, quality of consortium, resources
International Collaboration
-issues at stake:A) Development assistance
policy objectives, e.g. Millennium Development Goalstargets: poor countries, e.g. ACP
B) Strengthening EU competitiveness competing with industrialised countries (e.g. attracting excellence)collaboration for mutual gainstargets: more developed countries (e.g. BRIC)
C) Science diplomacycollaborating w. industrialised countries“ice breaking” when collaborating w. new partner countriesputting “meat on the bones” of S+T agreementsa sign of maturity of the FPs (openness)targets: OECD, all 3rd countries
International Collaboration
-what is new in FP7?
The management of thematic INCO projects moves from the INCO directorate to the thematic directorates
INCO-Health to Health Research
-better synergies with traditional collaborative projects in the theme
-greater visibility for INCO projects as part of a larger portfolio
1. All activities open for International Cooperation1. All activities open for International Cooperation International Cooperation Partner Countries (ICPCs) can participate in projects and receive EC funding Minimum number of participants: 3 from MS/AS
2. Specific International Cooperation Actions2. Specific International Cooperation Actions Address specific issues of partner countries or with a global character, on the basis of mutual interest and benefit Minimum number of participants: 2+2
(2 from MS/AS + 2 from ICPCs)
2 different avenues:
International Collaboration
in FP7
International Collaboration
in FP7 HealthExample of a SICA topics in the first Work Programme (deadlines in 2007)
Childhood and adolescent mental disorders
The research should be aimed at investigating paediatric mental disorders that have a high prevalence in countries of Central and Eastern Europe. The projects should use population genetics/genomics approaches and include bioinformatics/biostatistics to increase knowledge of the patterns of disease prevalence and develop possible diagnostic and therapeutic strategies as well as address prevention.
International Collaboration
in FP7 HealthExample of a SICA topics in the first Work Programme (deadlines in 2007)
Epidemiological investigations into long-term trends of population health as consequence of socio-economic transitions, including life-style induced health problems Investigations into tackling the burden of chronic diseases such as diabetes, cardiovascular and liver diseases, for identifying strategies at the population level to implement effective solutions to improve health. Specific International Cooperation Action. Targeted regions: Mediterranean Partner countries, Russia, Eastern European and Central Asia.
International Collaboration
in FP7 HealthOther initiatives
International activities in large scale data gathering for functional genomics
-organising and coordinating endeavours aiming at collecting, integrating and curating genomics, proteomics, population genetics, comparative and functional genomics data and/or samples of relevance to human health
Continuity in collaborative Health research to: develop new tools and technologies promote translational research optimise delivery of health care [ using usual FP funding mechanisms ]
&
A novel approach to improve drug development: The Innovative Medicines Initiative [ using the proposed Joint Technology Initiative in FP7 ]
Collaborative Health research in FP7
SUMMARY
Information
• EU research: http://ec.europa.eu/research
• Seventh Framework Programme: http://ec.europa.eu/research/fp7
• Information on research programmesand projects: http://www.cordis.lu/
• RTD info magazine: http://ec.europa.eu/research/rtdinfo/
• Information requests: http://ec.europa.eu/research/enquiries/
